26
Participants
Start Date
June 30, 2013
Primary Completion Date
December 31, 2019
Study Completion Date
March 31, 2020
Sitagliptin
The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Placebo
The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia
Children's Hospital of Philadelphia
OTHER
University of Pennsylvania
OTHER